CHICAGO--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, will present updates on three ...
SUMMERLIN, Nev., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful ...
Oral presentation highlights the resolving of inflammation and superior homing to bone marrow of CXCR4-enriched T regulatory cells. Poster presentation includes safety and efficacy data from phase 1b ...
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process using ...
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the ...
Houston, Texas and Tuebingen, Germany, April 23, 2025 - Immatics N.V. (NASDAQ: IMTX, "Immatics” or the "Company”), a clinical-stage biopharmaceutical company active in the discovery and development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback